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Cancer of the uterine corpus is the most common pelvic gynaecological malignancy in 
the United States of America and in most developed countries with access to 
sufficient health care. Approximately 95% of these malignancies are carcinomas of 
the endometrium with the other 5% being sarcomas. Currently there are no screening 
tests for cancer of the uterus in asymptomatic women. 
METHODS 
The study was a retrospective review of clinical records of patients managed at Inkosi 
Albert Luthuli Central Hospital (IALCH) , Durban, KwaZulu Natal, South Africa. 
Following ethical approval from the institutional ethics committee, charts of patients 
treated at the Inkosi Albert Luthuli Central Hospital Gynaecology-Oncology clinic 
between 01 June 2001 and 30 June 2006 were reviewed. Data was entered using an 
excel spreadsheet and then exported to Stata 9 (Stata Corp, College Station, TX) for 
recoding and analysis. 
RESULTS 
There were 118 women with uterine malignancy in the study period. Of 118 charts 
reviewed, data in six charts was incomplete and therefore could not be included in the 
study. There were 85 patients with endometrial carcinoma (75.~%) and 27 patients 
with uterine sarcoma (24.1 %). In this study the number of white women was too small 
"' 
to be compared with black women (n = 10 vs 51) but even so, African women and 
Indian women were associated with worse disease and outcome (only 1 White patient 
presented with advanced disease - EST). 
CONCLUSION 
The majority of patients seen at IALCH are African or Indian reflecting the 
demographics of the province. White patients seek medical assistance in the private 
sector due to better financial circumstances. Comparison between these groups is 
difficult but assessment of disease and disease behaviour in African and Indian 
patients was done and it was realised that when this group of patients presents early 
and appropriate management applied, the outcome is not that different from that 
described for white patients in other studies. 
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1. UTERINE MALIGNANCY 
Introduction 
Invasive neoplasms of the female pelvic organs account for almost 15% of all cancers 
in women (Winter and Goseweler, 2006). Cancer of the uterine corpus is the most 
common pelvic gynaecological malignancy in the United States of America and in 
most developed countries with access to sufficient health care. Approximately 95% of 
these malignancies are carcinomas of the endometrium with the other 5% being 
sarcomas. Currently there are no screening tests for cancer of the uterus in 
asymptomatic women. 
Endometrial cancer is primarily a disease of post menopausal women with the average 
age being 60 years at the time of diagnosis. Endometrial cancer is the commonest 
gynaecological cancer in the United States of America (USA). It ranks fourth in terms 
of incident cancers in women, and eighth in terms of age-adjusted mortality (Landis et 
aI, 1999). In the United States in 1999, endometrial cancer accounted for about 6% of 
all incident cancers and 2% of cancer deaths in women. Endometrial cancer is the 
ninth most common malignancy in females. Inherited forms of this malignancy exist. 
Mutations in mismatch repair genes result in hereditary non-polyposis colorectal 
cancer, which confers a lifetime risk of bowel cancer between 60 and 80% and an 
endometrial cancer risk of up to 60% (Evans, 1995). Current screening involves the 
use of transvaginal ultrasound and endometrial sampling where indicated. Genetic 
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testing for mutations in the mismatch repair genes is available, and if a pathogenic 
change is found within a family, predictive testing becomes available for unaffected 
family members. 
Uterine sarcomas tend to affect younger women and are more common in Black 
women. 
Uterine sarcomas encompass leiomyosarcoma, carcinosarcoma (CS), and endometrial 
stromal sarcoma according to traditional classification systems. During the last 15 
years, epidemiological, clinicopathogical, immunohistological, in vitro, in vivo, and 
molecular genetic research have found arguments to support the monoclonal nature of 
CS which points towards an endometrial origin (Ronnett et aI, 2002). Recent 
textbooks therefore classify CS as a subtype of endometrial cancer. The literature 
describing the epidemiology of these tumours is sparse with the most comprehensive 
reports describing these tumours published in 1986 and 1995. In 1986, Harlow et aI, 
noted an excess incidence of leiomyosarcoma and mixed mesodermal sarcoma for 
blacks compared with whites. However, little information was available at that time 
regarding survival, stage distribution, and treatment. The subsequent report by Platz 
and Benda (1995) acknowledged leiomyosarcoma and mixed mullerian 
tumours/carcinosarcomas as the most common of the sarcomas and noted that blacks 




I. ENDOMETRIAL CARCINOMA 
i. Introduction 
Endometrial cancer occurs primarily in postmenopausal women and is increasingly 
virulent with advancing age. The role of oestrogen in the development of most 
endometrial cancers has clearly been established. Any factor which increases 
exposure to unopposed oestrogen increases the risk for endometrial cancer. In the 
United States of America (USA), it is the most common malignancy of the female 
genital tract with about 39,300 new cases annually, resulting in more than 6,600 
deaths (Lurain, 2002). From 1986 to 1990, approximately 19% of US Surveillance, 
Epidemiology and End Results (SEER) Program cases were diagnosed in women less 
than 55 years of age. However, the age-specific incidence (per 100,000) peaked at 70-
74 years, which was 2.85 times the rate reported at 50 to 54 years (Schottenfeld, 
1995). The incidence of endometrial cancer in women under 50 years was 2.19 times 
higher in the United States. African-American women with endometrial cancer have 
more advanced disease and less favourable tumour grade than do White women (Hill 
et aI, 1995 and Liu et aI, 1995). Aziz et al (1993) also found Black patients to have 
poorer survival rate when compared to White patients. They also presented with more 
advanced disease than White females. Aziz et al (1993) reviewed 290 patients 
between 1975 and 1990 who presented at the Health Science Centre at Brooklyn and 
Kings County Hospital Centre of which 47.2% were black and 46.9% were white. Of 
the patients who presented in stage III disease, 88.89% were black and 11.1% were 
white (p = 0.034), and with grade III disease, 70.5% were black and 29.5% were 
white (p = 0.008). Seventy two percent of positive lymph nodes were in black patients 
compared to the 28% in white patients (p = 0.01). The overall ten-year corrected 
survival for white and black patients was 72% and 40%, respectively (p = 0.0003). 
Hill et al (1995) reported that although the incidence of uterine carcinoma is lower 
among African-American women compared with white women, the mortality rates 
are higher for African-American patients. 
ii. Risk factors 
Majority of risk factors and medical conditions associated with endometrial cancer are 
related directly or indirectly to the levels and metabolic effects of the reproductive 
hormones, namely oestrogen and progestogens (Schottenfeld, 1995). These risk 
factors include: 
• Parity. Nulliparous women have 2 to 3 times the risk of parous patients. It was 
initially observed in England and Wales that single women and married 
women without children had higher death rates from uterine corpus cancer 
than married parous women (Brinton et aI, 1992). It is not certain whether 
spontaneous miscarriages influence a woman's risk of endometrial cancer but 
an increased risk associated with induced abortions has been reported 
(McPherson et aI, 1996) 
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• Late menopause (occurring after 52 years) is associated with increased risk for 
endometrial cancer 2.4 times compared with that in women whose menopause 
occurred before 49 years of age. Endometrial cancer risk is also increased in 
women with long and irregular menstrual cycles (Henderson et aI, 1983). Most 
studies have found that early age at menarche (generally defined as before age 
11 or 12 years) is associated with 1.5-4 fold increase in risk of endometrial 
cancer (Elwood et aI, 1997 and Brinton et aI, 1992). 
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• Obesity is associated with a 3 to 10 times increased risk for endometrial 
cancer, with some studies finding significant increasing risk with increasing 
measures of central adiposity, after adjustments for body mass index (BMI) 
(Swanson et aI, 1993). Post-menopausal obese women are known to have 
higher endogenous oestrogens than lean women due to the aromatization of 
androstenedione in adipose tissue (Enriori and Reforzo, 1984). Obesity is also 
associated with reduced levels of sex hormone-binding globulin, which would 
further increase the amount of bioavailable oestrogen (Davidson et aI, 1981). 
• Hormone Replacement Therapy (HRT) without progestins increases the risk 
for endometrial cancer 4 to 8 times. By far the most consistent, and possibly 
the most controversial, factor associated with endometrial cancer is use of 
oestrogen replacement therapy. An increase in the incidence of endometrial 
cancer in the 1970s followed a marked increase in the sales of oestrogen for 
treatment of menopausal symptoms in the United States between 1962 and 
1975. (This increase in incidence was not paralleled by an increase in 
mortality from the disease) As a corollary, when rates of prescription of 
oestrogens began to decline in the late 1970s, a decrease in the incidence of 
endometrial cancer followed. Administration of cyclic progesterone (for at 
least 10 days of each treatment cycle) appears to mitigate the continuous 
mitotic stimulation of the endometrium by unopposed oestrogen therapy 
(Weiderpass et aI, 1999a), and its incomplete shedding. Progesterone 
antagonizes the effect of oestrogen by decreasing oestrogen receptors and 
increasing the activity of enzymes that metabolize oestradiol to less potent 
metabolites. 
• Diabetes mellitus is associated with increased risk of 1.3 to 2.8 times, and 
other conditions like Hypertension and Hypothyroidism have been associated 
with endometrial cancer, but a causal relationship has not been confirmed 
(Lurain, 2002). One possible explanation is that these conditions are simply 
markers of obesity (lung, 1997). Some have found that both associations 
became less consistent after adjustment for body mass, others that only the 
association with diabetes persisted (Brinton et aI, 1992), although others have 
found both to persist after adjustment not only for body mass but also for other 
confounding factors, including parity, oestrogen replacement therapy use and 
smoking status (Elwood et aI, 1997).It has also been suggested that the 
increased risk associated with diabetes and hypertension may be restricted to 
obese or overweight women 
• Family history of endometrial carcinoma is found in 15% of cases (du Toit, 
2001). Very little research has examined the question of whether women with 
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a family history of endometrial cancer is at increased risk of the disease. Some 
have observed a small (50%) increase in risk associated with a family history 
of 
endometrial cancer (Parazzini et aI, 1994). A genetic predisposition to the 
development of (non- polyposis) colon cancer, pancreatic, ovarian and breast 
carcinoma occurs in an autosomal condition, the Lynch Type II syndrome. 
• The risk of endometrial hyperplasia progressing to carcinoma is related to the 
presence and severity of cytologic atypia. Kurman et al (1985) found that 
progression to carcinoma occurred in 1 % of patients with simple hyperplasia, 
3% of patients with complex hyperplasia, 8% of patients with atypical simple 
hyperplasia, and 29% of patients with atypical complex hyperplasia. 
• Endogenous oestrogen; women with polycystic ovarian syndrome (peDS) are 
anovulatory and are thus at increased risk of endometrial carcinoma. Ovarian 
granulosa cell tumours are associated with endometrial hyperplasia and 
carcinoma due to their oestrogenic effects on the endometrium. These 
conditions appear to be especially linked to the occurrence of endometrial 
cancer in young women. The diagnosis of polycystic ovarian syndrome has 
been made in up to 30% of cases with endometrial cancer in selected groups of 
pre-menopausal women. 
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111. Factors decreasing the risk 
• Grand multiparity and Intrauterine Device 
With intense placental production of progestagens, pregnancy protects against 
endometrial cancer. Hinkula et al in 2002 and Chubak et al in 2004 reported that 
nulliparity is a risk factor that is more important if infertility is also present whereas 
grand multiparity protects against endometrial carcinoma. The use of an intrauterine 
device and tubal ligation have also been associated with a lower risk (Hubacher and 
Grimes, 2004). Whether a Mirena provides any further protection from endometrial 
carcinoma is unclear (Suvanto-Luukkonen et aI, 1995). 
• Smoking 
A number of studies have found that women who have ever smoked are at reduced 
risk of endometrial cancer, although several have suggested that this association is 
restricted to post-menopausal women (Stockwell and Lynman, 1987 and Parazzini et 
aI, 1994). The reduced risk of endometrial cancer in smokers even controversial is 
thought to provide further evidence of an anti-oestrogenic effect of smoking. The 
other arguement is that rather than affecting risk of endometrial cancer by reducing 
oestrogen, smoking may act by increasing levels of circulating androgen (Austin et aI, 
1993). Cigarette smoking has also been considered as a possible effect modifier of the 
associations between other factors , such as oestrogen use and obesity and endometrial 
cancer. Some studies have found the protective effect of smoking to be greater among 
postmenopausal women using oestrogen rather than the ones not using it, although 
other studies have found no significant interaction between smoking and oestrogen 
replacement therapy (Levi et aI, 1993). 
• Oral-contraceptive use 
That use of the combined oral contraceptive pill (oestrogen plus progestogen) reduces 
the risk of endometrial cancer and has been reported consistently. Long-term use of 
combined oral contraceptives appears to reduce the risk further, and the protective 
effect lasts for 20 or more years after discontinuation. Results of some studies (but not 
all) suggest that the protective effect of the combined oral contraceptive pill does not 
depend on the dose of the progestogen: the risk is similar whether the progestogen 
content is high or low (Weiderpass et aI, 1999b and Parslov et aI, 2000). 
• Physical activity 
The close relationships between diet, physical activity and body mass have made it 
difficult to assess the independent risks of the three on endometrial cancer. Whether 
physical activity plays a role via its association with obesity or whether it has an 
independent effect on risk of endometrial cancer is not clear. The only thing clear 
from the literature is that increased levels of physical activity reduce serum oestrogen 
levels (Cauley, 1989). 
• Diet of some phyto-oestrogens 
There have been suggestions of a protective effect of increasing phyto-oestrogen 
consumption on risk of endometrial cancer among postmenopausal women, even if 
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they are obese (Goodman et aI, 1997 and Xu et aI, 2004). The effect of eating a diet 
rich in soy throughout a lifetime cannot be compared with use of soy extracts given 
after the menopause. Unfer et al in 2004 reported that a daily intake of 150 mg 
isoflavones consisting of genistein (40 - 45%), daidzein (40 - 45%), and glycitein (10 
_ 20%), for 5 years has been associated with endometrial hyperplasia. Alcohol use is 
associated with raised oestrogen concentrations. Epidemiological studies, however, do 
not support a positive association between alcohol use and endometrial cancer as 
shown for breast cancer (Bandera et aI , 2003). 
II. CLINICAL FEATURES 
i. Symptoms 
About 90% of women with endometrial carcinoma present with vaginal bleeding or 
discharge as their only presenting complaint. Less than 5% of women diagnosed with 
endometrial cancer are asymptomatic (Lurain, 2002). In the absence of symptoms, 
endometrial cancer is usually detected as the result of investigation of abnormal 
Papanicolaou smear results, or an incidental finding post hysterectomy or evaluation 
of an abnormal finding on a pelvic ultrasound or computed tomography (CT) scan 
obtained for an unrelated reason (Dubeshter, et aI, 1991). Abnormal peri-menopausal 
and post-menopausal bleeding should always be taken seriously and be properly 
investigated, no matter how minimal. Vaginal discharge due to secondary infection of 
the tumour or a pyometra may be the presenting complaint and pain is usually a late 
presentation of the disease and is associated with metastatic spread (du Toit, 2001). 
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ii. Signs 
Physical examination seldom reveals any evidence of endometrial carcinoma, 
although obesity and hypertension are commonly associated constitutional factors. 
Lymph nodes should be palpated, especially the supraclavicular and inguinal lymph 
nodes. Abdominal examination is usually unremarkable except in advanced cases in 
which ascites, hepatic or omental metastases may be palpable. Gynaecological 
examination usually does not reveal much, but the introitus and suburethral area 
should be assessed carefully. 
III. DIAGNOSIS AND SPECIAL INVESTIGATIONS 
• Out-patient endometrial aspiration biopsy is the accepted first step in 
evaluating a patient with abnormal uterine bleeding or suspected endometrial 
pathology (Chambers and Chambers, 1992). This usually follows 
transvaginal ultrasound assessment of the endometrium (looking for 
thickened endometrium). Endometrial cancer is mostly diagnosed 
histologically from endometrial tissue obtained with miniature endometrial 
biopsy devices (generally based on the plastic disposable Pi pelle de Cornier 
prototype) (Amant et aI, 2005). A meta-analysis of the value of Pipelle 
biopsy for the diagnosis of atypical hyperplasia or endometrial cancer 
calculated sensitivity of 81-99% and specificity of about 98% and this was 
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further confirmed by a systematic quantitative review of 11 published studies 
done by Dijkhuizen et al in 2000 and Clark et al in 2002. 
• Hysteroscopy and dilation and curettage should be reserved for situations in 
which cervical stenosis or patient tolerance does not permit adequate 
evaluation by aspiration biopsy; bleeding recurs after a negative endometrial 
biopsy, or the specimen obtained is inadequate to explain the abnormal 
bleeding (Gimpleson and Rappold, 1988). 
• Transvaginal ultrasound is useful for evaluating abnormal uterine bleeding 
and selecting patients for additional testing (Bourne et aI, 1991). The finding 
of an endometrial thickness greater than 4 mm, a polypoid endometrial mass, 
or a collection of fluid within the uterus requires further evaluation (Lurain, 
2002). 
• A pap smear is an unreliable diagnosis test because only 30 - 50% of patients 
with endometrial cancer have abnormal Pap test results (Zucker et aI, 1985). 
• A chest x-ray, abdominal ultrasound, full blood count and serum chemistry 
(includes renal and liver function test) are investigations performed routinely 
in some centres while in others they are done as part of pre-treatment 
evaluation. 
IV. CLASSIFICATION OF ENDOMETRIAL CARCINOMAS (Gordon 
and Ireland, 1994) 
• Endometroid adenocarcinoma 
80% 
Usual type >50% 
Variants _ Villoglandular or papillary 2% 
- Secretory 1% 
- With squamous differentiation 15-25% 
• Mucinous carcinoma 5% 
• Papillary serous carcinoma 3-4% 
• Clear cell carcinoma 5% 
• Squamous carcinoma 1-2% 
• Undifferentiated carcinoma <1% 
• Mixed carcinoma <1% 
a) Endometriod adenocarcinoma 
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Accounts for about 80% of endometrial carcinoma (Gordon and Ireland, 1994). These 
tumours are composed of glands that resemble normal endometrial glands. They have 
columnar cells with basally oriented nuclei, little or no intracytoplasmic mucin, and 
smooth intraluminal surfaces. About 15-25% of endometriod carcinomas have areas 
of squamous differentiation. They are then known as endometrial carcinoma with 
squamous differentiation and their behaviour is largely dependent on the grade of the 
glandular component (Zaino et aI, 1991). A villoglandular configuration is present in 
about 2% of endometriod carcinomas (Sutton et aI, 1987). The cells are arranged 
along fibro vascular stalks, giving a papillary appearance but maintaining the 
characteristics of endometriod cells. Secretory carcinoma is a rare variant of 
endometriod carcinoma that accounts for about 1 % of cases (Tobon and Warkins, 
1985). It occurs mostly in women in their early postmenopausal years and is 
associated with an excellent prognosis. These tumours are composed of well 
differentiated glands with intracytoplasmic vacuoles similar to early secretory 
endometrium. 
Histological grading applies only to endometriod carcinomas. Serous and clear-cell 
carcinomas are classed as high grade by definition. According to the system of the 
International Federation of Gynaecology and Obstetrics (FIGO), an endometrioid 
carcinoma of grade 1 consists of well-formed glands, with no more than 5% solid 
non-squamous areas (areas of squamous differentiation are not deemed to be solid 
tumour growth) (Creasman, 1987). Carcinomas of grade 2 consist of 6-50% and those 
of grade 3 of more than 50% solid non-squamous areas (Zaino et aI, 1995). The 
tumour is upgraded from grade 1 to 2, or from grade 2 to 3, if there is striking 
cytological atypia. Most endometroid carcinomas are well to moderately 
differentiated and arise on a background of endometrial hyperplasia. These tumours, 
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also known as type 1 (low-grade) endometrial carcinomas, have a favourable 
prognosis (Bokhman, 1983). They are associated with long-duration unopposed 
oestrogenic stimulation. About 10% of endometrial cancers are type 2 (high-grade) 
lesions. Women with such tumours are at high risk of relapse and metastatic disease. 
These tumours are not oestrogen driven, and most are associated with endometrial 
atrophy; surgery is commonly followed by adjuvant therapy. The histological type is 
either poorly differentiated endometrioid or non-endometrioid. 
b) Mucinous Carcinoma 
Melhem and Tobon in 1987 reported that about 5% of endometrial carcinomas have a 
predominantly mucinous pattern in which more than half of the tumour is composed 
of cells with intracytoplasmic mucin. Their behaviour is similar to that of 
endometroid carcinoma and the prognosis is good. 
c) Uterine Papillary Serous Carcinoma (UPSC) 
Uterine papillary serous carcinoma (UPS C) is an uncommon aggressive type of 
endometrioid adenocarcinoma that was delineated by Hendrickson et al in 1982 as a 
clinico-pathological entity distinct from endometrioid carcinoma. Attention was 
drawn primarily to the presence of psammoma bodies and predominantly papillary 
architecture, although solid areas can be present focally in the dilation and curettage 
material (D & C).Uterine Papillary Serous Carcinoma is an aggressive variant of 
endometrial cancer found in 5% of cases. A higher incidence of deep myometrial 
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invasion, lymph-vascular space involvement, lymph node metastases, extra uterine 
disease, and positive peritoneal cytology and implants is characteristic. Even with 
surgical stage I cancer, the 5-year survival rate is 60%. Uterine Papillary Serous 
Carcinoma histologically resembles papillary serous carcinoma of the ovary. 
Although adjuvant chemotherapy is helpful, UPSC does not have the same duration of 
response to cytotoxic agents (eg, paclitaxel, carboplatin) as its ovarian counterpart. 
The first report on the use of paclitaxel in UPSC was a case report by Resnik and 
Taxy (1996) who described a dramatic response in an advanced UPSC tumour after 
three cycles of paclitaxel and carboplatinum given as neoadjuvant therapy. Zanotti et 
al (1999) treated 24 patients with UPSC with paclitaxel (175 mg/m2) alone or 
paclitaxel (175 mg/m2) combined with carboplatin area under curve (AUC = 5) or 
cisplatin (75 mg/m2). Eighteen patients received the regimens in the adjuvant setting. 
Eleven patients received one or more courses of this combination for recurrent 
disease. A median progression-free survival (PFS) of 30 months (range 8-61 months) 
was seen in patients treated in the adjuvant setting. An objective response indicated by 
normalisation of CA 125 was seen in eight of nine patients treated for residual disease 
after initial surgery (median PFS of 13 months, range 5-38 months), while an 
objective response was seen in seven out of eleven patients with recurrent disease 
(median PFS of9 months, range 4-18 months).Often, elements of clear cell carcinoma 
are associated with UPSc. Widespread metastases and death can occur even in those 
cases in which the tumour is confined to the endometrium or to an endometrioid 
polyp. 
d) Clear Cell Carcinoma 
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The concept of clear-cell carcinoma as being of mesonephric origin and designated as 
'mesonephroma' was introduced in 1939 by Schiller to describe a subtype of ovarian 
tumour which resembles renal carcinoma and tumours originating from the 
mesonephric duct system. Scully and Barlow (1967) related the origin of the latter 
group of tumours to the Mullerian epithelium rather than the mesonephros and 
proposed the descriptive term ' clear-cell carcinoma' (CCC). The prognostic 
implication of CCC was not recognized until 1976 when Kurman and Scully (1976) 
reported a series of 21 cases with an unfavourable clinical course. In the early 
literature, survival for CCC was usually given for clinically staged patients with an 
overall survival ranging from 21 to 60%. Abeler and Kjostard (1996) in the largest 
single institution study from The Norwegian Radium Hospital (NRH) (181 patients) 
demonstrated a 5 and 10 year actuarial disease-free survival rate of 43 and 39% 
respectively (for all stages). The 5-year survival for pathological stage I CCC of 54% 
and for stage II of 27% was lower than that reported by Carcangiu and Chambers 
(1992) of 72% and 59% respectively. These tumours classically occur in older women 
and are very aggressive types of endometrial cancer. 
e) Squamous Carcinoma 
This is a rare type. This tumour has a poor prognosis, with estimated 36% survival 
rate in patients with clinical stage I disease. 
V. STAGING OF ENDOMETRIAL CARCINOMA 
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Since 1998, endometrial cancer has been staged surgically. Prior to this, the disease 
was staged clinically, since almost all patients were treated with pre-operative 
radiotherapy, only information gained at initial dilation and curettage could be 
reliably used for prognostic purposes, all information obtained by examining the 
uterine specimen having been affected to some degree by the radiotherapy (Lawton, 
2003). 
International Federation of Gynaecology and Obstetrics (FIGO) (1988) 
Staging for Carcinoma of the Corpus Uteri 
Stage* Description 
IIA (Gl, G2, G3) I ITumOf limited to endometrium 
I 
IB (G1, G2, G3) Invasion of less than one half of the myometrium 
IC (G1, G2, G3) Invasion of more than one half of the myometrium 
IIA (G1, G2, G3) IEndocervical gland involvement 
I 
lIB (Gl, G2, G3) Icervical stromal involvement 
I 
IlIA (Gl, G2, G3) Invasion of serosa and/or adnexa and/or positive peritoneal 
cytologic results 
IIIB (G1, G2, G3) IMetastases to vagina 
I 
IIIC (G 1, G2, G3) Metastases to pelvic and/or para-aortic lymph nodes 
lR 
IVA (G1, G2, Invasion of bladder and/or bowel mucosa 
G3) 
IVB Distant metastases including intra-abdominal and/or inguinal 
lymph nodes 
*Carcinoma of the corpus is graded (G) according to the degree of histological 
differentiation: G 1 = 5 percent or less of a solid growth pattern; G2 = 6 to 50 
percent of a solid growth pattern; G3 = more than 50 percent of a solid growth 
pattern. 
From International Federation of Gynecology and Obstetrics. Annual report on the 
results of treatment in gynaecologic cancer (Sherphard, 1989). 
VI. MANAGEMENT 
i. Surgical management 
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a) Abdominal Hysterectomy 
Type 1 endometrial cancer spreads primarily via the lymphatic system and is often 
limited to pelvic nodes. Total abdominal hysterectomy and bilateral salpingo-
oophrectomy are the primary operative procedures for carcinoma of the endometrium. 
Most cases of endometrial cancer are stage 1 disease, which means that the primary 
tumour is confined to the corpus and can be excised entirely, with the myometrial 
thickness providing a barrier to spread to surrounding pelvic structures. Using this 
conservative approach, tumours are then divided into low-risk and high-risk to select 
the need for adjuvant radiotherapy which is given to irradiate pelvic nodes in case of 
nodal involvement as well as the vault where there is a risk of recurrence. Some 
gynaecological oncologists advocate slicing open the uterus immediately following its 
removal in order to eyeball the degree of myometrial invasion as a means of 
determining whether to proceed to lymphadenectomy. A recent prospective study by 
Franchi et al (2000) indicated that visual inspection correlated with microscopic 
assessment in 85% of cases. However, the sensitivity of determining >50% was lower 
at 72%. Whilst some would support this technique, it is not accurate enough to be 
recommended as a routine. Kilgore et al (1995) suggested that lymphadenectomy may 
be of some therapeutic benefit in their cohort study. They reviewed over 600 patients 
of whom, 212 had multiple site pelvic node sampling of which, 205 had limited node 
sampling and 208 had no node sampling at all. All patients had a hysterectomy and 
bilateral salpingo-oophrectomy with peritoneal cytology. They concluded that the 
overall survival rate for the patients who had multiple node sampling was better than 
patients who had none. Whether lymphadenectomy is curative in endometrial cancer 
remains controversial. Recent findings suggested that it was curative in women with 
?O 
grade-3 endometrial cancer, when more than 11 nodes were removed (Cragun et aI, 
2005). Furthermore, in a study from Scotland including 703 patients with endometrial 
cancer, deficient staging was associated with poorer survival (Crawford et aI, 2002). 
The first multicentre randomised trial to investigate the curative value of standard 
lymphadenectomy for endometrial cancer of stages 1 and 2 is the recently closed UK 
MRC ASTEC trial. Less aggressive surgical approach has been proposed by Mariani 
et al (2001). In their series, pelvic lymphadenectomy and radiotherapy were 
abandoned in patients with endometriod cancer of grade 1 or 2 with greatest surface 
dimension of 2 cm or less, myometrial invasion of 50% or less, and no intraoperative 
evidence of macroscopic disease. Among 328 patients, 5-year overall cancer-related 
survival was 97% and recurrence-free survival 96%. 
b) Laparoscopic surgery 
Although the results of randomised trials are still lacking, in experienced hands, 
laparoscopy-assisted vaginal hysterectomy is feasible when operating for endometrial 
cancer. (Yu et aI, 2005). It also presents the opportunity to take fluid for cytology, 
peritoneal biopsy samples, lymph nodes, and omentum samples in a single procedure. 
Amant et al (2005) compared clinical outcomes in women who had surgical staging 
for early-stage endometrial cancer by laparoscopy (n=80) or by laparotomy (n=105) 
during the same period. Exclusion criteria for laparoscopy included poor uterine 
descensus, largest uterine diameter from ultrasonography of more than 10 cm, Body 
Mass Index (BMI) more than 35 kg/m2, and history of previous laparotomy or pelvic 
radiotherapy. The mean age (62 vs 66 years; p=0.012) and BMI (26 vs 31 kg/m2; 
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p<O.OOl) were lower in the laparoscopy group than in the laparotomy group. 
Although the operation was slightly longer for patients in the laparoscopy group (169 
vs 152 min; p=0.063), they had less blood loss (344 vs 505 ml; p=0'0002) and a 
shorter hospital stay (5.6 vs 10.1 days; p<O.OOl). After follow-up of 55 months, 
multivariate analysis showed no difference in progression-free survival (odds ratio 
0.89; p=0.52) or overall survival (0.96; p=0.63). They concluded that due to absence 
of randomised trials on this issue, laparoscopy is a valuable alternative to laparotomy 
in selected patients. Manipulation of tumour, including macroscopically involved 
lymph nodes, should be avoided to prevent the rare occurrence of port-site metastasis. 
Furthermore, the use of an intrauterine manipulator should be avoided, since it results 
in a high frequency of positive peritoneal cytology and might contribute to vaginal-
cuff recurrence (Sonoda et aI, 2001 and Schneider 2004). Where macroscopic extra 
uterine disease or macroscopically positive pelvic lymph nodes are found conversion 
of the incision into a midline is recommended. Maylard incision or metal 
transabdominal traction sutures (Ventrofil) for midline incisions are frequently used in 
obese women with the aim to decrease wound morbidity. 
Since 1992, there have been several reports that have documented the feasibility of 
laparoscopic-assisted vaginal hysterectomy with bilateral salpingo-oophrectomy and 
laparoscopic retroperitoneal lymph node sampling for staging and treatment of 
patients with endometrial cancer (Boike et aI, 1994 and Gemignani et aI, 1999). Holub 
et aI, (2002) illustrated that laparoscopic assisted surgical staging of endometrial 
cancer is safe as an open procedure. The laparoscopic procedure may also be 
considered for endometrial malignancy which typically occurs in obese and elderly, 
high risk women. Holub et aI, (2002) compared 177 patients who had laparoscopic 
surgery with 44 patients who had open surgery and followed them for 33.6 months 
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and found no difference with respect to recurrence or survival rate. The only 
disadvantage was that the laparoscopic approach took longer than open surgery. 
c) Vaginal Hysterectomy 
Vaginal hysterectomy may be considered for selected patients who are extremely 
obese and have a poor medical status, or for patients with extensive uterovaginal 
prolapse (Lurain, 2002). Although these patients will tolerate vaginal surgery better, it 
may be difficult to assess the extent of the disease in the pelvis and abdomen. The 
disadvantage is that bilateral salpingo-oophrectomy is technically difficult and lymph 
node sampling cannot be performed. Vaginal hysterectomy is, therefore, particularly 
suitable for patients who are at low risk for extra uterine spread disease. Chan et aI, 
(2001) found a survival rate of 94% in patients with stage I disease with/ without 
postoperative radiotherapy. Vaginal hysterectomy is clearly preferable to radiation 
therapy alone, but generally should be reserved for specific patients. Peters et al 
(1983) report of 56 patients with stage I disease treated by vaginal hysterectomy, with 
or without adjunctive therapy, showed a 94% 5 year survival rate. The update of this 
series by Lelle et al (1994) added four additional patients. The crude survival rate at 5 
and 10 years was 91.1% and 87.1%, respectively, with only one patient dying of 
cancer 6 years after primary treatment. 
ii. Postoperative Adjuvant Therapy 
a) Radiation therapy 
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Primary surgery followed by individualized radiation therapy has become the most 
widely accepted treatment for early-stage endometrial cancer (Lurain, 2002). Several 
series have demonstrated radiotherapy to be an effective treatment for patients with 
inoperable endometrial cancer (Kupelian et aI, 1993 and Lehoczky et aI, 1991). 
Creutzberg et al (2000) showed that the 5-year survival rate of patients who had 
radiotherapy postoperatively was not different from the group who had radiotherapy 
alone (85% vs. 81 %). They randomized their patients identified as medium-risk 
(grade 1 tumour with >50% invasion, grade 2 tumours with any degree of invasion 
and grade 3 with superficial invasion) into Total Abdominal Hysterectomy (TAH) and 
Bilateral Salpingo-ophorectomy (BSO) alone or surgery plus postoperative 
radiotherapy. The decision to treat a patient who has endometrial cancer with 
radiation alone must involve a careful analysis of the relative risks and benefits of 
surgery. When radiotherapy is recommended in addition to surgery in contemporary 
management of endometrial cancer it is most often given as post-operative adjuvant 
therapy. In the past, pre-operative radiation was more frequently used but this 
approach has lost favour due to delay in definitive treatment, potential loss of 
pathological information and inability to tailor adjuvant therapy appropriately to 
specific surgico-pathological findings. Kucera et aI, (1990) reported on a large series 
of 605 patients who were treated with primary TAH and BSQ, of which 10% 
underwent retroperitoneal lymphadenectomy. All patients received vaginal 
brachytherapy. However, external beam pelvic radiation was given only to 229 
selected patients who had more deeply invasive and higher grade tumours (grade 1 
and 2/3 myometrial invasion, or grade 2 or 3 and 1/3 invasion). Using this treatment 
paradigm, the authors noted that survival in patients with adverse intrauterine features 
was similar to that in more favourable patients, with 5 year survival rates 
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approximating 90% in both groups. The results suggested that the addition of pelvic 
radiotherapy was able to compensate for the otherwise poorer outcomes expected for 
patients with unfavourable intrauterine pathological findings. Contributing to the 
controversy over the role of adjuvant radiation therapy is the variability with which 
different investigators characterize overall patient prognosis. It is clear that there 
exists a large proportion of endometrial cancer patients who enjoy very favourable 
prognosis and for whom no adjuvant therapy is warranted. Inclusion of such low-risk 
cases (stage 1, grade 1 or 2) in clinical studies of adjuvant radiotherapy can only 
diminish the likelihood of observing potential benefit in patients with higher-risk 
tumours (>stage 1c and grade 3). Well designed prospective studies are needed to 
evaluate the role of adjuvant radiation in patients with intermediate and high-risk 
disease. 
b) Chemotherapy 
Cytotoxic chemotherapy has no proven role in the treatment of early-stage disease but 
is used as a palliative treatment in patients with advanced disease. High cure rates by 
surgery and radiotherapy have precluded much interest in adjuvant chemotherapy in 
the majority of patients. Chemotherapy has been found to be useful in the 
management of uterine papillary serous carcinoma (2-10% of all endometrial cancers) 
(Price et aI, 1993). Price et al (1993) used cisplatin, doxorubicin and 
cyclophosphamide in 19 patients radically operated on without any residual tumour. 
Eight stage I patients were alive without evidence of disease after a median follow up 
of 24 months. Of the remaining 11 patients who had extrauterine disease at diagnosis, 
eight were dead of disease at a median of 14 months. Chemotherapy has not been 
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shown to be beneficial as far as recurrence of disease is concerned and no better 5 
year survival (Morrow et aI, 1990 and Burke et aI, 1994). Only five randomized 
control trials of non-hormonal combination chemotherapy in advanced disease have 
been reported and just two have been published in peer-reviewed journals (Flemming 
et aI, 2000 and Aapro et aI, 1994). There are only three published randomized trials of 
chemotherapy in combination with hormonal therapy (Ayoub et aI, 1988 and Cohen et 
aI, 1984). Because of this lack of properly researched data treatment decisions are 
therefore made largely on the results of small phase II trials. In the current era of 
evidence-based medicine, this fact makes such decisions difficult. However 
appropriate use of systemic chemotherapy in selected patients with advanced or 
recurrent disease appears justified and may result in a palliative benefit. The most 
active single agents in clinical trials are doxorubicin, cisplatin, carboplatin, paclitaxel, 
epirubicin and ifosfamide. Use of combination regimens produces substantial 
response rates in phase II and III clinical trials. However, these high responses rates 
do not appear to translate into dramatic improvements in survival and overall median 
survival remains short (7-10 months). Until more concrete evidence becomes 
available the current approach as far as use of chemotherapy is concerned will 
continue. 
c) Hormonal therapy 
The profound effects of progesterone on the normal endometrium and the inherent 
hormonal sensitivity of this tissue led to the concept that progestins may be useful in 
the treatment of endometrial cancer. Factors predicting a favourable response to 
progestins included a long hiatus between primary therapy and the appearance of 
metastasis, a histologically well-differentiated endometrial adenocarcinoma, and a 
pulmonary site of metastasis. In favourable cases, pulmonary metastases regressed 
within 2 months of the initiation of therapy and disappeared by 4 to 6 months. 
Responsive osteolytic lesions calcified, resulting in symptomatic relief of pain and 
disability although standard therapy for endometrial cancer is hysterectomy and 
bilateral salpingo-oophorectomy with appropriate staging, selected patients have been 
treated with progestational agents as primary therapy in an attempt to preserve 
childbearing potential. Farhi et al (1986) described ten cases of endometrial cancer 
arising in women under the age of 25. The slides were reviewed by at least two 
pathologists in order to distinguish these cases from adenomatous/atypical 
hyperplasia. Seven of the ten patients demonstrated the clinical characteristics of 
women with polycystic ovarian syndrome. Nine of the tumours were well-
differentiated endometrioid adenocarcinomas and were limited to the endometrium. In 
one case, a moderately-differentiated adenosquamous carcinoma involved an ovary 
and the pelvic wall. In five cases, progestins were used as primary therapy; three of 
the patients had no further evidence of tumour on repeat endometrial biopsy. One of 
the three patients successfully treated with progestins subsequently delivered two term 
pregnancies. 
Lawton (2003) prescribed hormonal therapy to patients after the diagnosis of 
endometrial cancer (i.e. before hysterectomy) and to almost all patients after surgery 
')7 
either in an immediate adjuvant setting or at relapses. Patients with that were found to 
have positive for estrogen and progesterone receptors responded best to progestin 
therapy. Among 115 patients with advanced endometrial cancer who were treated 
with progestin's, 75% (42 of 56 patients) of those with detectable progesterone 
receptors in their tumours before treatment responded, compared to only 7% without 
detectable progesterone receptors (4 of 59 patients) (Kauppila, 1989). A receptor-poor 
status may predict not only poor response to progestins but also a better response to 
cytotoxic chemotherapy. Tamoxifen is a triphenylethylene derivative similar to 
diethylstilbestrol. The citrate salt of the trans isomer is used clinically because of its 
increased affinity for the oestrogen receptor. The customary dosage is 20 mg a day, 
and the drug is readily absorbed after oral administration. The 'anti-oestrogen' 
tamoxifen is, in reality, the first selective oestrogen receptor modulator (SERM), a 
new category of therapeutic agents which mimic the effect of oestrogens in some 
tissues, but act as oestrogen antagonists in others. Based on prior experience with 
breast cancer, tamoxifen, either as a single agent or in combination with other 
hormones, has been used in the treatment of advanced and recurrent endometrial 
carcinoma. These studies were initiated at a time the agonist action of tamoxifen in 
the endometrium was not yet appreciated. There are few studies done to date and all 
show no response to tamoxifen. As a result, it is unlikely that patients with advanced 
or recurrent endometrial cancer unresponsive to progestational agents will experience 
a response to tamoxifen as a single agent. 
CHAPTER 2: 
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I. UTERINE SARCOMA 
i. Introduction 
Uterine sarcomas are relatively rare tumours of mesodermal origin. They constitute 
2% to 6% of uterine malignancies (Harlow et aI, 1986). There is considerable 
evidence for a higher incidence of uterine sarcomas in black women when compared 
to white women (Amant et aI, 2005). The literature describing the epidemiology of 
these tumours is sparse; with the most comprehensive reports describing these 
tumours published in 1986 and 1995. In 1986, Harlow et al. noted an excess incidence 
of leiomyosarcoma and mixed mesodermal sarcoma for blacks compared with whites; 
however, little information was available at that time regarding survival, stage 
distribution, and treatment. The subsequent report by Platz and Benda (1995) 
acknowledged leiomyosarcoma and mixed mullerian tumours/carcinosarcoma as the 
most common of the sarcomas and noted that blacks with carcinosarcoma were less 
likely to be diagnosed with localized disease compared to whites. In the United States, 
incidence rates for malignant tumours of the uterine corpus are lower among black 
women than among white women whereas the mortality rates are higher (Sherman 
and Devesa, 2003). Black women with carcinosarcoma were less likely to present 
with stage I disease than white women (Brooks et aI, 2004). The risk for uterine 
sarcoma is higher in women with a body mass index >27, one year before diagnosis 
and lower in cigarette smokers, this indicates a possible link to estrogen metabolism. 
Malignant Mixed Mullerian Tumours (MMMT) or Carcinosarcoma almost always 
occur after menopause, at a median age of 62 years. These tumours are usually found 
in association with other conditions such as obesity, diabetes mellitus, and 
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hypertension. Uterine sarcomas encompass leiomyosarcoma, carcinosarcoma (CS), 
and endometrial stromal sarcoma (EST). 
i Carcinosarcoma 
The biphasic cellular population found in carcinosarcoma entered the sphere of 
interest of many researchers, who focused on the question whether this tumour 
originated from one (monoclonal theory) or two cell populations. A wide spectrum of 
methods has been elaborated to answer this question. During the last 15 years, 
epidemiological, clinic-pathogical, immuno-histological, in vitro and in vivo, and 
molecular genetics research have found arguments to support the monoclonal nature 
of carcinosarcoma that pointed towards an endometrial origin. Recent textbooks 
therefore classify carcinosarcoma as a subtype of endometrial cancer as reported by 
Ronnett et al in 2002. Consequently, the designation endometrial carcinosarcoma 
corresponds best to its tissue origin and should be used instead of uterine 
carcinosarcoma. Amant et al (2005) found carcinosarcoma to present more with 
bleeding than other symptoms and that it had more metastatic potential when 
compared with other sarcomas. Carcinosarcomas or homologous malignant mixed 
miillerian tumours (MMMT) typically have an endometrioid carcinoma, usually a 
higher grade, and an undifferentiated spindle cell sarcoma. The sarcomatous portion 
of the tumour may exhibit an ESS pattern, if differentiated. Malignant Mixed 
Mullerian tumours are termed heterologous only if identifiable extra uterine histology 
is demonstrated. Malignant Mixed Mullerian tumours are characterized by early extra 
uterine spread and lymph node metastases. Extra uterine disease and lymph node 
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metastases are directly related to depth of myometrial invasion and the presence of 
cervical disease. The presence of heterologous elements does not seem to affect 
prognosis in terms of the initial extent of disease. New evidence points to a substantial 
expression of c-kit receptors in MMTs. 
ii Endometrial Stromal Tumours and Leiomyosarcomas 
Stromal tumours and leiomyosarcoma occur primarily in perimenopausal women 
between 45 and 50 years of age and there is no relationship to parity (Lurain, 2002). 
Just like other uterine sarcomas, they have a higher incidence and poorer prognosis in 
African women. Lower abdominal pain is the commonest presenting symptom 
especially in leiomyosarcoma and poorer prognosis in black Mrican women than in 
white women. The histopathologic diagnosis of Leiomyosarcomas (LMS) can be 
unclear until the time of definitive surgery. Diagnosis of LMS is believed to depend 
on the number of mitoses (or mitotic count) and the degree of cellular atypia. The 
diagnosis of LMS versus leiomyoma and leiomyoma with high mitotic activity or 
uncertain malignant potential is based on the metastatic potential of the tumour. The 
mitotic count and cellular atypia correlates to this metastatic potential. Although 
controversy continues to exist regarding the diagnosis of LMS, several studies support 
the theory that if the mitotic count is less than 5 per 10 high-powered fields (HPF), the 
tumour is a leiomyoma with negligible metastatic potential regardless of the presence 
of any cellular atypia. Likewise, the tumour has a high metastatic potential and is 
considered an LMS, regardless of the degree of cellular atypia, if the mitotic count is 
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greater than 10 per 10 HPF. Some believe that mitotic count alone is not a good 
indicator of metastatic potential. 
Endometrial Stromal Tumours (EST) can be divided into 2 categories: low-grade EST 
(LGEST) and high-grade EST (HGEST). Low Grade Endometrial Stromal Tumours 
(LGEST) is characterized by fewer than 5-10 mitoses per 10 HPF and minimal 
cellular atypia. These tumours can have a recurrence rate of up to 50% but 
demonstrate indolent growth and late recurrences. High Grade Endometrial Stromal 
Tumours (HGEST) have a greater mitotic count and degree of cellular atypia. Risk of 
recurrence in both LGEST and HGEST is determined not only by histological 
characteristics but also by surgical stage and extent of disease. Interestingly, some 
authors believe that true HGEST does not exist. 
II. TREATMENT OPTIONS 
The first step in the treatment of early uterine sarcoma should be exploratory 
laparotomy. Total abdominal hysterectomy and bilateral salpingo-oophorectomy 
should be performed in all patients except premenopausal women with 
leiomyosarcoma (Lurain, 2002). Most studies have found adjuvant post-operative 
radiation therapy to be of value in decreasing pelvic recurrences and thereby 
increasing quality of life in patients with localized carcinosarcoma and stromal 
tumours, but not leiomyosarcomas (Knocke et aI, 1998 and Molpus et aI, 1998). 
Adjuvant therapy has been shown to improve the survival for women with stage II _ 
IV disease (Brooks et aI, 2004). The literature has revealed that black women have a 
higher incidence of the most common uterine sarcomas. Brooks et aI, (2004) believes 
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that the poorer survival of black women with uterine sarcoma may be due in part to 
lower referral for radiation therapy (or other adjuvant therapy) with extension of 
disease beyond the uterus, given the higher prevalence of stage II disease. It has been 
shown that when black and white women receive the same adjuvant therapy with 
disease at the same stage the survival rate is not that different even with other cancer 
like cervical and breast. 
In advanced disease, progestin therapy and doxorubicin-based chemotherapy have a 
role. Because of the increased tendency for LMS to spread via blood and recur at 
distant/extra-pelvic sites, whole-pelvic radiotherapy is relatively ineffective. 
Chemotherapy with doxorubicin, ifosfamide, etoposide, and/or cisplatin may be used 
of LMS. Recently, gemcitabine and taxotere combination therapy has shown promise 
in unresectable LMSs of different sites. Patients with MMT limited to the pelvis 
benefit from whole-pelvic radiation with respect to local control. Those patients with 
evidence of extra-pelvic disease may respond to additional postoperative therapy with 
doxorubicin, cisplatin, and/or ifosfamide. These cytotoxic therapies have 
demonstrated up to a 20% complete response rate in patients with advanced or 
recurrent disease. Therefore radiation therapy provides local tumour control with no 
consistent improvement in survival rates. Based on the evidence available 
chemotherapy and hormonal therapy are better suited for evidence of extra-pelvic 
spread but yield somewhat inconsistent results. For these reasons, postoperative 
therapy for uterine sarcomas is quite variable. 
Recurrence is very common when dealing with uterine sarcomas. Stage I uterine 
sarcomas recur in up to 50% of cases. The overall 5 year survival rate for LMS is 15-
25%. Stage I LMS has a 58% and 70% 5 year survival after surgery without and with 
radiation therapy, respectively. Recurrences commonly occur in the lungs mostly and 
very rarely localized. Stage I LGEST and HGEST have 5 year survival rates of 80% 
and 50%, respectively. As expected, advanced disease has a much worse prognosis, 
with a 5 year survival rate of 0-33% for stages II-IV. Early-stage carcinosarcoma has 
a 5 year survival rate of approximately 50%, while stages II-IV have a 5-year survival 
rate of 5-15%. Localized disease, pelvic or extra-pelvic, may be responsive to surgical 
excision or radiation therapy. Although doxorubicin, ifosfamide, and cisplatin have 
been studied and used in treatment of distant multi-focal recurrent disease, no 
definitive choice of chemotherapeutic has been recommended for the treatment of 
recurrent uterine sarcomas. Evaluation of imatinib mesylate (Gleevec) in advanced 
and recurrent carcinosarcoma is in progress. 
14. 
CHAPTER 3: 
I. The aims of the study 
1. To audit the profile of patients with uterine malignancies (carcinomas and 
sarcomas) presenting to the gynaecological oncology clinic at IALCH between 
2001 and 2006. 
2. The aim of the study was to compare uterine malignancies between white women 
and black women who presented at Inkosi Albert Luthuli Central Hospital 
Gynaecological Oncology clinic between June 2001 and June 2006. 
II. OBJECTIVES 
• To compare the type of uterine malignancy and stage at the time of 
presentation. 
• To compare management options taken (surgical vs radiotherapy vs 
chemotherapy) and the outcome there after. 
• To compare any differences in outcome of disease amongst the various ethnic 
groups presenting to the oncology clinic at IALCH. 
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III. METHODS 
a) The Study design 
The study was a retrospective review of clinical records of patients managed at Inkosi 
Albert Luthuli Central Hospital (IALCH) , Durban, KwaZulu Natal, South Africa. 
Following approval from the institutional post graduate (higher degree committee) 
and ethics committee, charts of patients treated at the Inkosi Albert Luthuli Central 
Hospital Gynaecology-Oncology clinic between 01 June 2001 and 30 June 2006 were 
reviewed. A data collection sheet (Appendix 1) was used to capture data. All 
information was kept confidential. The data was then submitted to the statistician (Ms 
Cathy Connolly, MRC Durban) for analysis. 
IV. STATISTICAL ANALYSIS 
Data was entered using an excel spreadsheet and then exported to Stata 9 (Stata Corp, 
College Station, TX) for recoding and analysis. Demographic and clinical data are 
presented for each cancer group. However, the numbers in each cancer group were 





There were 118 women with uterine malignancy that presented or were referred to 
IALCH gynaecological oncology clinic during the study period. Of 118 charts 
reviewed, data in six charts was incomplete and therefore could not be included in the 
study. There were 85 patients with endometrial carcinoma (75.9%) and 27 patients 
with uterine sarcoma (24.1 %). 
DEMOGRAPHIC PROFILE, CLINICAL DATA AND 
SPECIAL INVESTIGATIONS crable 1) 
There were far less white patients (9.8%) in the whole study when compared with 
African patients (47%), who were the majority and Indian women (41%). The 
majority of patients were African (48%) in the endometrial carcinoma group and 
Indian in the Uterine Sarcoma group (48%). The majority of women in the 
endometrial group were greater than the age 60 whereas in the sarcoma group the 
majority were less than 60 years. Most women fell into the Para 1 to 4 group as 
compared with the other groups. The commonest presenting symptom was vaginal 
bleeding in both the endometrial carcinoma and sarcoma groups. The majority of 
patients {endometrial carcinoma (49%) vs sarcoma (63%)} had hypertension as 
associated disease and diabetes mellitus was found in 27% of patients in the 
endometrial group. Only 31 % of Pap smears showed malignancy in the endometrial 
carcinoma group and 25.9% of patients in the whole sarcoma group. Urea and 
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creatinine were found to be normal in the majority of patients in both sarcoma and 
endometrial group, so was abdominal ultrasound and chest x-ray in both groups of 
uterine malignancies. 
TREATMENT, STAGING AND COMPLICATIONS OF SURGERY (Table 2) 
Surgery was found to be the primary mode of treatment in both endometrial (89%) 
and uterine sarcoma (82%) groups. Total Abdominal Hysterectomy (TAH) and 
bilateral salpingo-oophorectomy was the commonest type of surgery for both groups. 
Lymph node dissection was done in 9% of patients with endometrial carcinoma. 
Majority of patients who were seen at the combined oncology clinic had surgery 
performed by the referring hospital where the clinician had not performed surgical 
staging (lymphadenectomy). A large number of these patients however, were not 
candidates for surgical staging due to anaesthetic and medical risk factors. The 
patients who had lymphadenectomy performed were carefully selected according high 
risk factors for node involvement (policy of the unit). Most patients (53%) in the 
endometrial group presented with FIGO stage I whereas only 18% of the sarcoma 
presented in stage I and the majority presented with stage 4 disease. Then 25% of 
patients with endometrial carcinoma presented with stage 3 which was the second 
most common stage at the time of presentation for this group. Radiotherapy was the 
commonest adjuvant therapy for endometrial carcinoma (53%) which is in keeping 
with the literature. Chemotherapy combined with radiotherapy was rarely used in the 
endometrial carcinoma group, whereas in the sarcoma group, the majority of patients 
had chemotherapy (33%) alone. There were 30% of sarcoma patients with local side 
effects from chemotherapy while most of the endometrial carcinoma group (88%) had 
no side effects from the chemotherapy. Eighty percent of endometrial carcinoma 
patients completed therapy compared to only 52% of uterine sarcoma patients. Nine 
percent of endometrial carcinoma patients defaulted treatment and only 2 defaulted 
treatment in the sarcoma group. Nine percent of endometrial carcinoma patients 
defaulted treatment and only 2 defaulted treatment in the sarcoma group. Ninety five 
percent of endometrial carcinoma group were still alive on completion of this review 
and 19% of the uterine sarcoma group died during follow up. 
HISTORY, RADIOTHERAPY SIDE EFFECTS AND HIV STATUS crable 3) 
Only 3 patients in the whole study group had recorded use of hormone replacement 
therapy (HRT) prior to presentation at the clinic. Of the patients who received 
radiotherapy (53% in the endometrial group and 18% in the sarcoma group), only 2 
had side effects (bowel stricture and cystitis) in the sarcoma group and 10 in the 
endometrial group (6% with GIT side effects and 5% with gynaecological side 
effects). In the majority of patients (93% in the endometrial group and 92.5% in the 
sarcoma group) there was no family history of cancer of any origin. However, 5% of 
patients in the endometrial group had family history of breast carcinoma and 2% had 
that of endometrial carcinoma. Seven percent of endometrial carcinoma patients were 
found to be HIV positive and 18.5% of patients with sarcoma were HIV positive. Of 
the 10 overall HIV positive patients, 3 had stage I disease (endometrial carcinoma), 3 
had stage III disease (1 in the sarcoma group and 2 in the endometrial carcinoma 
group) and 4 had stage IV disease (all being in the sarcoma group). But the number of 
HIV positive patients was too small to be compared with the HIV negative group. 
39 
None of the HIV positive patients were on Anti - retroviral treatment and the average 
CD4 cell count was 346 !A/cells. Only one HIV positive patient was noted to have died 
from pneumonia, the rest were still being followed up or receiving treatment for 
whatever type of cancer that they were diagnosed with. Of note there were no HIV 
positive patients with uterine malignancy at IALCH until July 2005. EST was 
excluded from significant testing since there was only 1 patient who presented with 




Connell et a1. (1999) retrospectively compared the clinicopathologic factors, 
socioeconomic status, treatments, and outcomes of 70 black and 302 white women 
treated for surgically staged endometrial carcinoma at their institution. They found 
black women to have higher-grade tumors, less favourable histological findings, more 
co-morbid illnesses, and lower socioeconomic indices. On univariate analysis, black 
women were found to have a worse 5-year disease-free survival than white women 
(52.8% versus 75.2%; p = 0.001). Other significant factors included stage, grade, 
lymph node status, extension to the uterine serosa, cervical involvement, histology, 
adnexal involvement, lymphovascular invasion, myometrial invasion, positive 
peritoneal cytology, level of education, and household income. After controlling for 
pathologic and socioeconomic differences in multivariate analysis, race remained a 
significant prognostic factor (p = 0.008; hazard rate 2.0; (95% confidence interval 1.2 
- 3.5). They then concluded that the black race was associated with significantly worse 
outcomes, even after controlling for clinicopathologic and socioeconomic factors 
when it came to endometrial carcinoma. 
Amant et al (2005) traced 146 patients of which 9 patients were ineligible. 
Histological subtypes of the remaining 137 patients were - 50 (37%) grade 3 
endometrioid carcinoma, 54 (39%) serous or clear cell carcinoma (non-endometrioid 
carcinoma), and 33 (24%) carcinosarcomas. The distribution of early stage disease (I 
and II) was 67, 46, and 78% for grade 3 endometrioid, non-endometrioid, and 
carcinosarcoma, respectively. Although they could not trace differences in 
hematogenic and transperitoneal spread among the three subtypes, they reported that 
non-endometrioid and carcinosarcomas were more likely to spread to pelvic and para-
aortic lymph nodes (p< 0.01). Using univariate analysis, both stage (p < 0.006) and 
histological type appeared to determine the outcome, whereas lympho-vascular space 
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infiltration (p< 0.25) and age (p< 0.07) were not significantly different between the 
three histological subtypes that were studied. Cox Regression multivariate analysis 
performed on the 127 women suffering from the three histological subtypes suggested 
that both stage III-IV disease (p < 0.00001) and histological type (carcinosarcoma) 
(p < 0.003) were of prognostic significance. Analyzing cases limited to stage I-II 
endometrial cancer, 24/28 (86%) grade 3 endometrioid, 18/24 (75%) non-
endometrioid, and 11/25 (44%) carcinosarcomas survived, suggesting a worse 
outcome for endometrial carcinosarcoma when compared to the other subtypes 
(p < 0.008). A higher incidence of pulmonary metastases explained the worse 
outcome for early stage carcinosarcoma (p < 0.006), whereas the incidence of liver 
metastasis, transperitoneal spread, or recurrences in lymph nodes or vagina were 
comparable between the three pathologic sUbtypes. They then concluded that although 
endometrial carcinosarcoma originates from epithelial cancer, the intrinsic more 
aggressive tumour biology suggests that this subtype should not be incorporated in 
studies on high-risk epithelial endometrial cancer. 
Aziz et al (1993) reviewed 290 patients between 1975 and 1990 who presented at the 
Health Science Centre at Brooklyn and Kings County Hospital Centre of which 
47.2% were black and 46.9% were white. They found that of the patients who 
presented in stage III disease, 88.89% were black and 11.1% were white (p = 0.034). 
They also reported that with grade III disease, 70.5% were black and 29.5% were 
white (p = 0.008). Seventy two percent of patients with positive lymph nodes were in 
black patients compared to the 28% in white patients (p = 0.01). Their overall ten-year 
corrected survival for white and black patients was 72% and 40%, respectively (p = 
0.0003). 
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In our study the number of white women was too small to be compared with black 
women (n = 10 vs 51) but even so, African women and Indian were associated with 
worse disease and outcome (only 1 White patient presented with advanced disease -
EST). There were 41.2% of African women with early stage disease (Stage I) 
compared with 50% of the Indian women. Over 82% of all patients were treated with 
surgery as the primary mode of treatment (African = 88.2%, Indian = 84% and white 
= 82%). Of the 12.9% serous papillary adenocarcinoma subtype, 54% were Indian 
and 36% were African and 1 patient was Coloured. Three coma five percent of Indian 
patients had serous subtype of endometrial carcinoma. Currently there is no literature 
comparing Indian women with endometrial cancer to black women with endometrial 
cancer but looking at our results one wonders whether disease progression is worse in 
the South African Indian community when compared to the African women. 
Randall and Armstrong (2003) analyzed 1992 to 1998 Surveillance, Epidemiology, 
and End Results data for 21,561 women with epithelial cancers of the endometrium. 
They found unadjusted hazard ratio (HR) for death from endometrial cancer for 
African-American women compared with white women to be 2.57. However, African-
American women were significantly more likely to present with advanced-stage 
disease and have poorly differentiated tumours or tumours with an unfavourable 
histological type and were significantly less likely to undergo definitive surgery at all 
stages of disease. After adjusting for tumour and socio-demographic characteristics 
lowered the HR for African-American women to 1.80. Further adjustment for the use 
of surgery reduced the HR to 1.51. They found that the association between surgery 
and survival was stronger among white women (HR 0.26) than among African-
American women (HR 0.44). They then concluded that African-American women 
with endometrial cancer are significantly less likely to undergo primary surgery and 
41 
have significantly shorter survival than white women with endometrial cancer. Racial 
differences in treatment are associated with racial differences in survival. The 
association between use of surgery and survival is weaker among African-American 
than white women, raising questions about potential racial differences in the 
effectiveness of surgery. 
Even though we could not compare white women with African women there were 
many patients with endometriod subtype (82.4%) and over 88% of African patients 
had surgery as primary mode of treatment and only 4 patients were recorded to have 
demised. White women could not be compared to African women because of the 
small number of white patients, but there was no major difference in disease 
progression, response to treatment and stage of presentation when African women 
were compared to the Indian women. 
Brooks et al. (2004) used cases from Surveillance, Epidemiology, and End Results 
(SEER) program to compare uterine sarcoma among women >35 years of age. Using 
data from 1989 to 1999, they compared race-specific age-adjusted incidences, 
histological distributions, extent of disease at diagnosis, and race-specific survival. 
During the period of 1989-1999, 2677 women were diagnosed with uterine sarcoma, 
2098 (78%) of whom were white and 420 (16%) of whom were black, and 159 (6%) 
of whom were of other races. In their study the overall age-adjusted incidence for 
blacks was twice that of whites and more than twice that of women of other races (p < 
0.0001). Racial differences in the incidence of uterine sarcoma existed for 
leiomyosarcoma with blacks being affected more than other race groups (p < 0.01) 
and carcinosarcoma presenting the same picture (p < 0.001), but not for other 
histological types. Blacks with stage II disease were less likely to receive radiation in 
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addition to surgery compared to whites (33% vs. 54%, p < 0.05). Five year relative 
survival of patients with disease beyond the uterus was significantly longer for those 
who received radiation and surgery compared to those that received surgery alone. 
They then concluded that adjuvant therapy improved survival for women with stage 
II-IV disease and survival of black and white patients who received comparable 
treatment was similar. 
In our study there were 27 patients with uterine sarcoma so it was not possible to 
compare the different race groups. There were 8 Indian women with carcinosarcoma 
and 6 African women; 5 Indian women with leiosarcoma and 6 African women with 
only 1 white patient in this group. Seventy one percent of carcinosarcoma patients 
had surgery compared with 92% of patients with leiomyosarcoma even though only 
25% (Carcinosarcoma) and 14% (Leiomyosarcoma) presented in stage I. Twenty one 
percent of Carcinosarcoma patients demised and 17% of the leiomyosarcoma group. 
II. CONCLUSION 
Connell et al. (1999) retrospectively compared the clinicopathologic factors, 
socioeconomic status, treatments, and outcomes of 70 black and 302 white women 
who were treated for surgically staged endometrial carcinoma at their institution. 
4.') 
Black women had higher-grade tumours, less favourable histological findings, more 
co-morbid illnesses, and lower socioeconomic indices. Randall and Armstrong (2003) 
analyzed 1992 to 1998 Surveillance, Epidemiology, and End Results data for 21,561 
women with epithelial cancers of the endometrium. They found unadjusted hazard 
ratio (HR) for death from endometrial cancer for African-American women compared 
with white women to be 2.57. However, African-American women were significantly 
more likely to present with advanced-stage disease and have poorly differentiated 
tumours or tumours with an unfavourable histological type and were significantly less 
likely to undergo definitive surgery at all stages of disease. 
The majority of patients seen at IALCH are African or Indian reflecting the 
demographics of the province. White patients seek medical assistance in the private 
sector due to better financial circumstances. Therefore comparison between African 
and white patients was not possible but assessment of disease and disease behaviour 
in African and Indian patients was done and it was realised that when they present 
early and appropriate management applied, the outcome is not that different from that 
described for white patients in other studies. There is a need for a bigger and better 
review comparing white women to African women in South Africa so that we can 
compare it with what is reported in other countries. 
APPENDIXl 
DATA COLLECTION SHEET FOR PATIENTS WITH UTERINE TUMOURS 
RACE 
1- WH 2-AF 3- IN 
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4 
I I I 
AGE I I I 
1-i<40YRS) 2- (41-60YRS) 3- (61-80YRS) 4 
PARITY 
1- (<1) 2- (1-4) 3- (>4) 
PRESENTING SYMPTOMS 
1- BLE 2- PVD 3-PLM 4 
MEDICAL CONDITIONS 
4 -
1-DM 2-HPT 3-0TH NIL 
CLINICAL FEATURES 
BP I-NOR ABD MASS 1-<12W LMP 1-ING j 
2-HPT 2- >13W 2-GEN 
3-NIL 
INVESTIGATIONS 
PAP I-NEG HB I-LOW UREAl-NOR 
2-LGSIL 2-NOR 2-ABN 
3-HGSIL 
4-CAN HISTO 1- ENDO 
HIST SUBGROUP 2- LEIO 
1-ENDO 3-MMMT 
2-SER 4- EST 
3-MUCI 
4-SERPAP CREATININE CXR I-NOR U/S ABD 1- NOR 
5-CLEAR I-NOR 2-PLE 2- LIV 
2-ABN 3-ATE 3-HYD 
4-
4-MET ASC 
PRIMARY MODE OF TREATMENT 
1- SUR 2-XRT 3-SYM 
TYPES OF SURGERY 
1- TAH/BSO 2- VH 3-LVH ~ 
5-0MT 6-APE 7- TAH/LND/BSO 8 
FIGO STAGING 
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1A-1 1B-2 1C-3 
IIA- 4 IIB- 5 
IIIA- 6 IIIB- 7 IIIC- 8 
IYA- 9 IYB-10 11- NONE 
ADJUVANT THERAPY 
1- SUR 2-XRT 3-CHE ~ 
5-HOR 6-0TH 7- NIL 
COMPLICATIONS OF SX 
1- YES 2-NO 
SIDE EFFECTS OF CHEMO 
5-
haem - 1 GIT - 2 local - 3 renal - 4 NIL 
COMPLETION OF THERAPY 
1- YES 2- NO 
FOLLOW UP 
DEF-1 <lYR- 2 1-4YRS- 3 >4YRS- 4 
CLINICAL OUTCOME POST RX 
1- ALIVE 2- DEMISED 
FAMILY HISTORY 
1-CABRE 2- CAEND 3- CABOW 4 
5- CAOYA 
HRT 1- YES 2-NO 
S/EOFXRT GIT-1 2-NO GYN -3 










White BLE - DM - Diabetes BP Blood negative 
AF Bleeding 
African PVD 
IN - Indian vaginal 




Coloured PLM - Pelvic 
mass 





ENDO - TAR - Total SUR - Surgery 
pressure LGSIL - low 
NOR - Normal grade 
HPT - squamous 
Hypertension intraepithelial 
ABD - lesion. 
Abdominal HGSIL - High 
LMP - grade 
Lympadenopat squamous 
hy intraepithelial 
ING - Inguinal lesion. 
GEN- CAN - Cancer 
Generalized Hb 




















Serous Hysterectomy CHE - hydronephrosis rna 
MUCI - LVH - Chemotherapy 
Mucinous Laparoscopy CRT 
SERP AP - assisted Chemoradiothera 


























DEMOGRAPHIC PROFILE OF PATIENTS, CLINICAL DATA AND 
SPECIAL INVESTIGATIONS 
Sarcomas 
Endometrial Leio CS I EST 
"1 
(n - 85) (n = 12) (n- 14) (n - 1) 
n % n % N % N % 
Race 
White 10 12% 1 8% 0 0% 0 0% 
Mrican 41 48% 6 50% 6 43% 0 0% 
Indian 32 38% 5 42% 8 57% 1 100% 
Coloured 2 2% 0 0% 0 0% 0 0% 
Age 
< = 60 yrs 34 40% 9 75% 4 29% 0 0% 
> 60~rs 51 60% 3 25% 10 71% 1 100% 
Parity 
<1 10 12% 3 25% 2 14% 1 100% 
1 to 4 45 53% 9 75% 4 29% 0 0% 
>4 30 35% 0 0% 8 57% 0 0% 
Presenting symptoms 
BLE 80 94% 11 92% 13 93% 1 100% 
PVD 8 9% 1 8% 2 14% 0 0% 
PLM 0 0% 1 8% 0 0% 0 0% 
Other 0 0% 0 0% 0 0% 0 0% 
Medical Condition 
DM 23 27% 0 0% 4 29% 0 0% 
HPT 42 49% 6 50% 10 71% 1 100% 
Other 1 1% 0 0% 1 7% 0 0% 
Nil 32 38% 6 50% 2 14% 0 0% 
INVESTIGATIONS 
Pap smear 
Neg 55 65% 9 75% 9 64% 1 100% 
LGSIL 2 2% 1 8% 0 0% 0 0% 
HGSIL 2 2% 0 0% 0 0% 0 0% 
CAN 26 31% 2 17% 5 36% 0 0% 
Blood Pressure 
Low 53 62% 9 75% 7 50% 0 0% 
Normal 32 38% 3 25% 7 50% 1 100% 
Urea 
Normal 67 79% 9 75% 11 79% 0% 
Abnormal 18 21% 3 25% 3 21% 0% 
Creatinine 
Normal 76 89% 11 92% 10 71% 1 100% 
Abnormal 9 11% 1 8% 4 29% 0 0% 
Chest xray 
Normal 79 93% 8 67% 10 71% 0 0% 
PLE 3 4% 0 0% 1 7% 0 0% 
ATE 3 4% 4 33% 3 21% 0 0% 
ATE/MET 0 0% 0 0% 0 0% 1 100% 
U/SABD 
Normal 75 88% 8 67% 8 57% 0 0% 
LIV 2 2% 2 17% 2 14% 0 0% 
HYD 1 1% 0 0% 0 0% 0 0% 
ASC 6 7% 0 0% 4 29% 0 0% 
LIV/ASC 1 1% 2 17% 0 0% 1 100% 
*EST excluded from significance testing 
a. Presenting b. Medical 
symptoms condition 
BLE - bleeding DM - diabetes mellitus 
PVD - vaginal discharge HPT - hypertension 
PLM - pelvic mass 
c. Pap smear d. Chest xray 
Neg - negative PLE - pleural effusion 
LGSIL low grade squamous ATE - atelactasis 
intraepitheliallesion MET - metastasis 
HGSIL high grade squamous 
intraepitheliallesion 
CAN - cancer 
e. Ultrasound f. Sarcomas 
abdomen Leio - Leiomyosarcoma 
LIV -liver metastasis CS - Carcinosarcoma 
HYD - hydronephrosis EST - Endometrial Sarcoma Tumours 
ASC - Ascites 
Table 2: 
TREATMENT, STAGING AND COMPLICATIONS OF SURGERY 
Sarcomas 
Endometrial Leio CS EST 
(n = 85) (n = 12) (n= 14) (n = 1) 
n % n % N % N % 
Primary Mode of RX 
Surgery 76 89% 11 92% 10 71% 1 100% 
XRT 7 8% 0 0% 2 14% 0 0% 
SYM 2 2% 1 8% 2 14% 0 0% 
Types of Surgery 
TAH/BSO 63 83% 7 58% 10 71% 1 100% 
VH 4 5% 1 8.3% 0 0% 0 0% 
RADHY 1 1% 0 0 0 0% 0 0% 
TAH/LND/B 7 9% 1 8.3% 0 0% 0 0% 
TAH/BSO/OMT/APE 1 1% 0 0 0 0% 0 0% 
NIL 9 12% 3 25% 4 29% 0 0% 
FIGO STAGING 
1 45 53% 3 25% 2 14% 0 0% 
2 12 14% 1 8% 4 29% 0 0% 
3 21 25% 2 17% 3 21% 0 0% 
4 2 2% 6 50% 3 21% 1 100% 
no stage 5 6% 0 0% 2 14% 0 0% 
Adjuvant therapy 
XRT 45 53% 4 33% 1 7% 0 0% 
CHE 5 6% 3 25% 6 43% 0 0% 
XRT&CHE 9 11% 3 25% 5 36% 0 0% 
Nil 26 31% 2 17% 2 14% 1 100% 
Complications of Surgery 
Yes 14 16% 2 17% 2 14% 0 0% 
No 71 84% 10 83% 12 86% 1 100% 
Side effects of Chemo 
Haem 3 4% 0 0% 0 0% 0 0% 
GIT 2 2% 0 0% 1 7% 0 0% 
Local 3 4% 3 25% 5 36% 0 0% 
Renal 2 2% 1 8% 1 7% 0 0% 
Nil 75 88% 8 67% 7 50% 1 100% 
Completion of therapy 
Yes 68 80% 6 50% 8 57% 0 0% 
No 17 20% 6 50% 6 43% 1 100% 
Follow up 
Default 8 9% 0 0% 2 14% 0 0% 
< lyr 30 35% 4 33% 4 29% 1 100% 
14yrs 46 54% 6 50% 7 50% 0 0% 
> 4 yrs 1 1% 2 17% 1 7% 0 0% 
Clinical Outcome 
Alive 81 95% 10 83% 11 79% 1 100% 
Demised 4 5% 2 17% 3 21% 0 0% 
*EST excluded from significance testing 
a. Primary mode of treatment b. Types of surgery 
XRT - radiotherapy TAR - Total Abdominal Hysterectomy 
SYM - symptomatic BSO - Bilateral Salpingo-oophorectomy 
VH - Vaginal hysterectomy 
RADHY - Radical hysterectomy 
LND/B - Lymph node dissection/biopsy 
OMT - omentectomy 
APE - Appendecectom y 
c. Adjuvant therapy d. Side effects 
XRT - radiotherapy chemotherapy 
CHE - Chemotherapy Haem - haematological 
XRT & CHE - radiotherapy and chemotherapy GIT - gastro-intestinal 
Table 3: 
HISTORY, RADIOTHERAPY SIDE EFFECTS AND HIV STATUS 
Sarcomas 
Endometrial Leio CS EST 
(n = 85) (0 = 12) (n= 14) (n - 1) 
n % n % N % n % 
Family History 
CABRE 4 5% 1 8% 0 0% 0 0% 
CAEND 2 2% 0 0% 1 7% 0 0% 
Nil 79 93% 
HRT 
Yes 2 2% 
No 83 98% 
S/E ofXRT 
GIT 5 6% 
No 76 89% 
GYN 4 5% 
HIV Status 
Pos 6 7% 
Neg 64 75% 
Unk 15 18% 
*EST excluded from significance 
testing 
a. Family history 
CA BRE - carcinoma of the breast 
CA END - carcinoma of the 
endometrium 
h. HIV Status 
Pos - positive 
Neg - negative 











92% 13 93% 1 100% 
8% 0 0% 0 0% 
92% 14 100% 1 100% 
0% 1 7% 1 100% 
100% 13 93% 0 0% 
0% 0 0% 0 0% 
33% 1 7% 0 0% 
58% 8 57% 1 100% 
8% 5 36% 0 0% 
c. Side effects of radiotherapy 
GIT - gastro-intestinal 
GYN - gynaecological 
No - none 
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